Pacific Bio (PACB) Reports In-Line Q4 EPS, Misses on Revenue

Pacific Bio (NASDAQ: PACB) reported Q4 EPS of ($0.20), in-line with the analyst estimate of ($0.20). Revenue for the quarter came in at $39.2 million versus the consensus estimate of $40.61 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.

You May Also Be Interested In

• eToro Group (ETOR) Reiterated at Market Outperform by Citizens as EBITDA Rises 9%
• Ryman Hospitality prices $700M in notes to fund Orlando acquisition
• Aardvark Therapeutics (AARD) Tops Q2 EPS by 21c